Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

OptiBiotix inks sweet manufacturing deal with Indian food ingredients giant Tata Chemicals

The agreement gives Tata the exclusive rights to produce a sugar from OptiBiotix’s LP-LDL probiotic strain
Obese man
China (46mln) and India (30mln) rank second and third in having the highest number of overweight people in the world

Life sciences group OptiBiotix Health plc (LON:OPTI) has signed a manufacturing agreement with India-listed food ingredients giant Tata Chemicals.

It is an expansion of a deal the two inked last December and gives Tata, part of the Tata Group, the exclusive rights to produce a sugar from OptiBiotix’s LP-LDL probiotic strain.

WATCH: Opti boss on 'very good' deal with Tata

READ: Opti partners up with multinational as it targets Asian weight loss markets

The sugar – galacto-oligosaccharide – will be used in various food and over-the-counter products, subject to its successful development at pilot development.

When digested they stimulate the growth of ‘good’ gut bacteria, which Opti has showed can lead to improved health and help to tackle ‘chronic lifestyle diseases’ such as diabetes and obesity.

This agreement with Tata focuses on the Asian markets, particularly India, but Opti is in talks with other companies about manufacturing the cholesterol and blood pressure-lowering strain in other markets such as the US.

READ: OptiBiotix set to launch its cholesterol-reducing strain in US soon

“We believe the combination of OptiBiotix's ability to develop ingredients which can modify an individual's microbiome, and Tata's research and manufacturing expertise, international reputation, and global reach, places both companies at the forefront of global microbiome research and product development,” said OptiBiotix chief executive Stephen O’Hara.

“This agreement takes both companies further down the path of translating the science of the microbiome field into products which will improve the health and wellbeing of people around the world.”

City broker praises 'interesting' deal

"The announcement is interesting in that TATA recently launched its own GOS related first general health product and is a major supplier of pharmaceutical industries both within India and globally," said finnCap analyst Lorne Daniel.

"Whilst only in the earliest stages of development, we are encouraged by this announcement and continue to recognise the commercial milestones that OPTI's management are steadily and reliably delivering upon."

Shares rose 5.35%, or 3.8p, to 74.8p.

--Updates for broker comment, video link and share price--

View full OPTI profile View Profile

OptiBiotix Health plc Timeline

Related Articles

1504120610_biotechLatest.jpg
August 31 2017
The company is poised for a milestone-rich period over the next year or so
Workers at CERN
September 29 2017
The technology being developed is cheaper and smaller than the current units, which are almost prohibitively expensive
Cells
May 17 2017
Revenues are on the rise and the group’s efforts to bring in new business is delivering.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use